Canada markets open in 3 hours 38 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1500-0.0900 (-7.26%)
At close: 04:00PM EDT
1.2400 +0.09 (+7.83%)
Pre-Market: 05:27AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.2400
Bid1.2400 x 1100
Ask1.2400 x 3200
Day's Range1.1490 - 1.3700
52 Week Range1.1200 - 8.8700
Avg. Volume3,284,411
Market Cap123.043M
Beta (5Y Monthly)0.13
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    American College of Cardiology Program to Increase Cholesterol Screenings

    Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular d

  • GlobeNewswire

    Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

    ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 11, 2023 at 3:00 PM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investo

  • GlobeNewswire

    Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

    – In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17% risk reduction in MACE-4 and 20% risk reduction in MACE-3 – – No increase in development of new onset diabetes in patients randomized to bempedoic acid compared to placebo – ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two o